STAT+: Pharmalittle: We’re reading about a Lilly deal, an Intellia CRISPR rare-disease treatment, and more

STAT PlusNewsletterPharmalot Pharmalittle: We’re reading about a Lilly deal, an Intellia CRISPR rare-disease treatment, and more Sun Pharmaceutical agreed to acquire Organon in a deal valued at $11.75 billion Manage alerts for this article Email this article Share this article By Ed SilvermanApril 27, 2026 Pharmalot Columnist, Senior Writer Ed Silverman[email protected]Ed Silverman, a senior writer and Pharmalot columnist at STAT, has been covering the pharmaceutical industry for nearly three decades. He is also the author of the morning Pharmalittle newsletter and the afternoon Pharmalot newsletter. Good morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and invigorating because that oh-too-familiar routine of meetings, deadlines, and the like has returned with a vengeance. You knew this would happen, yes? To cope, we are relying, as always, on a cuppa stimulation. Our choice today is ginger honey. Feel free to join us. Remember, no prescription is required. Meanwhile, here are some tidbits to help you along. Best of luck accomplishing your goals today and, of course, do keep in touch. … Intellia Therapeutics disclosed that a single dose of its gene editing treatment dramatically reduced swelling attacks in patients with a rare genetic disorder in a Phase 3 trial, setting up a potential approval, STAT tells us. The therapy, known as lonvo-z, would be the second approved CRISPR-based medicine, after Vertex Pharmaceutical’s sickle cell treatment Casgevy. Intellia has already initiated a rolling submission with the agency. This would be the first in vivo treatment, meaning it edits patient DNA directly in the body. The question for Intellia and for the field will be how attractive the one-and-done approach will be to patients and doctors. Hereditary angioedema, or HAE, which affects around 20,000 patients in the U.S. and Europe, has seen an influx of new treatments over the last few years. Advertisement Sun Pharmaceutical agreed to acquire Organon in a deal valued at $11.75 billion, putting the Indian drugmaker on track to become one of the top three global players in women’s health, The Wall Street Journal notes. Sun, which specializes in generics and is one of the biggest pharma names in India by market cap, will fund the deal through a combination of internal cash resources and financing from banks. Organon, which was formed through a spinoff from Merck, has a portfolio of more than 70 products across women’s health and general medicines, including biosimilars, commercialized across 140 countries. Its 2025 revenue was $6.2 billion. The acquisition will help lift Sun into the top 25 global pharmaceutical companies, with a revenue of $12.4 billion. STAT+ Exclusive Story Already have an account? Log in This article is exclusive to STAT+ subscribers Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts. Already have an account? Log in Monthly $39 Totals $468 per year $39/month Get Started Totals $468 per year Starter $30 for 3 months, then $399/year $30 for 3 months Get Started Then $399/year Annual $399 Save 15% $399/year Get Started Save 15% 11+ Users Custom Savings start at 25%! Request A Quote Request A Quote Savings start at 25%! 2-10 Users $300 Annually per user $300/year Get Started $300 Annually per user View All Plans To read the rest of this story subscribe to STAT+. Subscribe Log In pharmalittle, STAT+ Submit a correction requestReprints Ed Silverman Pharmalot Columnist, Senior Writer Ed Silverman, a senior writer and Pharmalot columnist at STAT, has been covering the pharmaceutical industry for nearly three decades. He is also the author of the morning Pharmalittle newsletter and the afternoon Pharmalot newsletter. Newsletter Understand how science, health policy, and medicine shape the world every day Recommended Pharmalot April 24, 2026 STAT Plus: Up and down the ladder: The latest comings and goings Pharmalot April 24, 2026 STAT Plus: Pharmalittle: We’re reading about a Trump deal with Regeneron, reclassifying medical marijuana, and more Advertisement Pharmalot April 23, 2026 STAT Plus: Legislatures in Colorado and Virginia resist moves to constrain drug affordability boards Pharmalot April 23, 2026 STAT Plus: Pharmalittle: We’re reading about cheap telehealth visits, pharma withholding meds in Europe, and more Pharmalot April 22, 2026 STAT Plus: Pharmalittle: We’re reading about Medicare’s obesity drug pilot, an experimental Roche MS drug, and more Subscriber Picks